Last updated on March 2018

Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Subjects With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Dialysis-dependent Chronic Kidney Disease | Anemia
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • 18 years of age
  • Initiated chronic maintenance dialysis (either peritoneal or hemodialysis) for end-stage kidney disease within 16 weeks prior to Screening
  • Mean Screening hemoglobin between 8.0 and <11.0 g/dL (inclusive)

Exclusion Criteria:

  • Subjects meeting the criteria of ESA resistance within 8 weeks prior to or during Screening defined as follows
    1. epoetin: > 7700 units/dose three times per week or >23,000 units per week
    2. darbepoetin alfa: >100 mcg/week
    3. methoxy polyethylene glycol-epoetin beta: >100 mcg every other week or >200 mcg/month
  • Anemia due to a cause other than CKD or subjects with active bleeding or recent blood loss
  • Anticipated to recover adequate kidney function to no longer require dialysis
  • Uncontrolled hypertension
  • Severe heart failure at Screening (New York Heart Association Class IV)
  • Acute coronary syndrome (hospitalization for unstable angina, myocardial infarction); surgical or percutaneous intervention for coronary, cerebrovascular, or peripheral artery disease (aortic or lower extremity); surgical or percutaneous valvular replacement or repair; sustained ventricular tachycardia; hospitalization for CHF; or stroke within 12 weeks prior to or during Screening.
  • Hypersensitivity to vadadustat, darbepoetin alfa or any of their excipients

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.